You need to be logged in to view this video
John McCamant has spent 35 years on the front lines of biotech investing as an equities analyst and in venture capital. He has also edited the Medical Technology Stock Letter since the year 2000. In this session, he'll tell you about the methodology he uses to sift through hundreds of biotech companies to find the best in class drugs like MDGL for long-term growth. Plus, John will highlight the most attractive biotech opportunities in this premier growth sector for the rest of 2023 and beyond.
John McCamant
Medical Technology Stock Letter,
Editor
John McCamant joined the leading investment newsletter, Medical Technology Stock Letter, as an associate editor in 1987 and was named editor in August 2000. He has spent over 35 years on the front lines of biotechnology investing. In his previous role as an equities analyst for the American Healthcare fund, Mr. McCamant uncovered investment opportunities and guided investment strategy.
Trending Now
Filter By Category
Filter By Keywords
Loading...